{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:12:32Z","timestamp":1790856752224,"version":"4.1.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06496-1","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:45:46Z","timestamp":1747028746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology"],"prefix":"10.1186","volume":"23","author":[{"given":"Chen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao Yue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru Lu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"6496_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semcdb.2014.09.004","volume":"37","author":"SE Craig","year":"2015","unstructured":"Craig SE, Brady-Kalnay SM. Regulation of development and cancer by the R2B subfamily of RPTPs and the implications of proteolysis. Semin Cell Dev Biol. 2015;37:108\u201318. https:\/\/doi.org\/10.1016\/j.semcdb.2014.09.004.","journal-title":"Semin Cell Dev Biol Jan"},{"issue":"1","key":"6496_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2164-5-14","volume":"11","author":"J Besco","year":"2004","unstructured":"Besco J, Popesco MC, Davuluri RV, Frostholm A, Rotter A. Genomic structure and alternative splicing of murine R2B receptor protein tyrosine phosphatases (PTPkappa, Mu, Rho and PCP-2). BMC Genomics. 2004;11(1):14. https:\/\/doi.org\/10.1186\/1471-2164-5-14.","journal-title":"BMC Genomics Feb"},{"issue":"1","key":"6496_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00016.2002","volume":"83","author":"KG Johnson","year":"2003","unstructured":"Johnson KG, Van Vactor D. Receptor protein tyrosine phosphatases in nervous system development. Physiol Rev. 2003;83(1):1\u201324. https:\/\/doi.org\/10.1152\/physrev.00016.2002.","journal-title":"Physiol Rev Jan"},{"issue":"1\u20132","key":"6496_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0014-5793(91)81241-y","volume":"23","author":"MF Gebbink","year":"1991","unstructured":"Gebbink MF, van Etten I, Hateboer G, et al. Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase. FEBS Lett. 1991;23(1\u20132):123\u201330. https:\/\/doi.org\/10.1016\/0014-5793(91)81241-y.","journal-title":"FEBS Lett Sep"},{"issue":"1","key":"6496_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0378-1119(96)00684-1","volume":"20","author":"Y Yang","year":"1997","unstructured":"Yang Y, Gil MC, Choi EY, Park SH, Pyun KH, Ha H. Molecular cloning and chromosomal localization of a human gene homologous to the murine R-PTP-kappa, a receptor-type protein tyrosine phosphatase. Gene. 1997;20(1):77\u201382. https:\/\/doi.org\/10.1016\/s0378-1119(96)00684-1.","journal-title":"Gene Feb"},{"issue":"3","key":"6496_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1006\/bbrc.1996.1736","volume":"21","author":"Y Yang","year":"1996","unstructured":"Yang Y, Gil M, Byun SM, Choi I, Pyun KH, Ha H. Transforming growth factor-beta1 inhibits human keratinocyte proliferation by upregulation of a receptor-type tyrosine phosphatase R-PTP-kappa gene expression. Biochem Biophys Res Commun. 1996;21(3):807\u201312. https:\/\/doi.org\/10.1006\/bbrc.1996.1736.","journal-title":"Biochem Biophys Res Commun Nov"},{"issue":"5","key":"6496_CR7","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1128\/mcb.13.5.2942-2951.1993","volume":"13","author":"YP Jiang","year":"1993","unstructured":"Jiang YP, Wang H, D\u2019Eustachio P, Musacchio JM, Schlessinger J, Sap J. Cloning and characterization of R-PTP-kappa, a new member of the receptor protein tyrosine phosphatase family with a proteolytically cleaved cellular adhesion molecule-like extracellular region. Mol Cell Biol. 1993;13(5):2942\u201351. https:\/\/doi.org\/10.1128\/mcb.13.5.2942-2951.1993.","journal-title":"Mol Cell Biol May"},{"key":"6496_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-immunol-032414-112103","volume":"33","author":"CV Rothlin","year":"2015","unstructured":"Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. TAM receptor signaling in immune homeostasis. Annu Rev Immunol. 2015;33:355\u201391. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112103.","journal-title":"Annu Rev Immunol"},{"key":"6496_CR9","doi-asserted-by":"publisher","first-page":"272858","DOI":"10.1155\/2015\/272858","volume":"2015","author":"AP Adam","year":"2015","unstructured":"Adam AP. Regulation of endothelial adherens junctions by tyrosine phosphorylation. Mediators Inflamm. 2015;2015:272858. https:\/\/doi.org\/10.1155\/2015\/272858.","journal-title":"Mediators Inflamm"},{"issue":"28","key":"6496_CR10","doi-asserted-by":"publisher","first-page":"16712","DOI":"10.1074\/jbc.271.28.16712","volume":"12","author":"M Fuchs","year":"1996","unstructured":"Fuchs M, Muller T, Lerch MM, Ullrich A. Association of human protein-tyrosine phosphatase kappa with members of the armadillo family. J Biol Chem. 1996;12(28):16712\u20139. https:\/\/doi.org\/10.1074\/jbc.271.28.16712.","journal-title":"J Biol Chem Jul"},{"issue":"4","key":"6496_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc1837","volume":"6","author":"A Ostman","year":"2006","unstructured":"Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6(4):307\u201320. https:\/\/doi.org\/10.1038\/nrc1837.","journal-title":"Nat Rev Cancer Apr"},{"issue":"6","key":"6496_CR12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1110\/ps.062128706","volume":"15","author":"J Eswaran","year":"2006","unstructured":"Eswaran J, Debreczeni JE, Longman E, Barr AJ, Knapp S. The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1. Protein Sci. 2006;15(6):1500\u20135. https:\/\/doi.org\/10.1110\/ps.062128706.","journal-title":"Protein Sci Jun"},{"key":"6496_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.semcdb.2015.01.004","volume":"37","author":"S Bouyain","year":"2015","unstructured":"Bouyain S. Protein tyrosine phosphatases. Semin Cell Dev Biol. 2015;37:56\u20137. https:\/\/doi.org\/10.1016\/j.semcdb.2015.01.004.","journal-title":"Semin Cell Dev Biol Jan"},{"key":"6496_CR14","doi-asserted-by":"publisher","unstructured":"Anders L, Mertins P, Lammich S, Furin-, et al. ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin\u2019s transcriptional activity. Mol Cell Biol. 2006;26(10):3917\u201334. https:\/\/doi.org\/10.1128\/MCB.26.10.3917-3934.2006.","DOI":"10.1128\/MCB.26.10.3917-3934.2006"},{"issue":"1","key":"6496_CR15","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/gb-2006-7-1-r5","volume":"7","author":"AR Forrest","year":"2006","unstructured":"Forrest AR, Taylor DF, Crowe ML, et al. Genome-wide review of transcriptional complexity in mouse protein kinases and phosphatases. Genome Biol. 2006;7(1):R5. https:\/\/doi.org\/10.1186\/gb-2006-7-1-r5.","journal-title":"Genome Biol"},{"issue":"5","key":"6496_CR16","doi-asserted-by":"publisher","first-page":"e62852","DOI":"10.1371\/journal.pone.0062852","volume":"8","author":"S Agarwal","year":"2013","unstructured":"Agarwal S, Al-Keilani MS, Alqudah MA, Sibenaller ZA, Ryken TC, Assem M. Tumor derived mutations of protein tyrosine phosphatase receptor type K affect its function and alter sensitivity to chemotherapeutics in glioma. PLoS ONE. 2013;8(5):e62852. https:\/\/doi.org\/10.1371\/journal.pone.0062852.","journal-title":"PLoS ONE"},{"issue":"12","key":"6496_CR17","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.4049\/jimmunol.170.12.6363","volume":"15","author":"L Novellino","year":"2003","unstructured":"Novellino L, Renkvist N, Rini F, et al. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol. 2003;15(12):6363\u201370. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6363.","journal-title":"J Immunol Jun"},{"issue":"1","key":"6496_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1182\/blood-2006-11-059881","volume":"1","author":"JR Flavell","year":"2008","unstructured":"Flavell JR, Baumforth KR, Wood VH, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of hodgkin lymphoma cells. Blood. 2008;1(1):292\u2013301. https:\/\/doi.org\/10.1182\/blood-2006-11-059881.","journal-title":"Blood Jan"},{"key":"6496_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7554\/eLife.44597","volume":"29","author":"GW Fearnley","year":"2019","unstructured":"Fearnley GW, Young KA, Edgar JR, et al. The homophilic receptor PTPRK selectively dephosphorylates multiple junctional regulators to promote cell-cell adhesion. Elife. 2019;29:8. https:\/\/doi.org\/10.7554\/eLife.44597.","journal-title":"Elife Mar"},{"issue":"7","key":"6496_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00432-013-1421-5","volume":"139","author":"PH Sun","year":"2013","unstructured":"Sun PH, Ye L, Mason MD, Jiang WG. Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer. J Cancer Res Clin Oncol. 2013;139(7):1129\u201339. https:\/\/doi.org\/10.1007\/s00432-013-1421-5.","journal-title":"J Cancer Res Clin Oncol Jul"},{"issue":"2","key":"6496_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0006-8993(99)01179-8","volume":"1","author":"P Shen","year":"1999","unstructured":"Shen P, Canoll PD, Sap J, Musacchio JM. Expression of a truncated receptor protein tyrosine phosphatase kappa in the brain of an adult Transgenic mouse. Brain Res. 1999;1(2):157\u201371. https:\/\/doi.org\/10.1016\/s0006-8993(99)01179-8.","journal-title":"Brain Res May"},{"issue":"6","key":"6496_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ygeno.2007.03.001","volume":"89","author":"H Kose","year":"2007","unstructured":"Kose H, Sakai T, Tsukumo S, et al. Maturational arrest of thymocyte development is caused by a deletion in the receptor-like protein tyrosine phosphatase kappa gene in LEC rats. Genomics. 2007;89(6):673\u20137. https:\/\/doi.org\/10.1016\/j.ygeno.2007.03.001.","journal-title":"Genomics Jun"},{"issue":"11","key":"6496_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00335-007-9062-0","volume":"18","author":"A Asano","year":"2007","unstructured":"Asano A, Tsubomatsu K, Jung CG, Sasaki N, Agui T. A deletion mutation of the protein tyrosine phosphatase kappa (Ptprk) gene is responsible for T-helper immunodeficiency (thid) in the LEC rat. Mamm Genome. 2007;18(11):779\u201386. https:\/\/doi.org\/10.1007\/s00335-007-9062-0.","journal-title":"Mamm Genome Nov"},{"issue":"3","key":"6496_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.bbrc.2009.09.117","volume":"18","author":"N Erdenebayar","year":"2009","unstructured":"Erdenebayar N, Maekawa Y, Nishida J, Kitamura A, Yasutomo K. Protein-tyrosine phosphatase-kappa regulates CD4\u2009+\u2009T cell development through ERK1\/2-mediated signaling. Biochem Biophys Res Commun. 2009;18(3):489\u201393. https:\/\/doi.org\/10.1016\/j.bbrc.2009.09.117.","journal-title":"Biochem Biophys Res Commun Dec"},{"issue":"1","key":"6496_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mcb.14.1.1-9.1994","volume":"14","author":"J Sap","year":"1994","unstructured":"Sap J, Jiang YP, Friedlander D, Grumet M, Schlessinger J. Receptor tyrosine phosphatase R-PTP-kappa mediates homophilic binding. Mol Cell Biol. 1994;14(1):1\u20139. https:\/\/doi.org\/10.1128\/mcb.14.1.1-9.1994.","journal-title":"Mol Cell Biol Jan"},{"issue":"2","key":"6496_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/0968-0004(93)90049-s","volume":"18","author":"G Beckmann","year":"1993","unstructured":"Beckmann G, Bork P. An adhesive domain detected in functionally diverse receptors. Trends Biochem Sci. 1993;18(2):40\u20131. https:\/\/doi.org\/10.1016\/0968-0004(93)90049-s.","journal-title":"Trends Biochem Sci Feb"},{"issue":"24","key":"6496_CR27","doi-asserted-by":"publisher","first-page":"14247","DOI":"10.1074\/jbc.270.24.14247","volume":"16","author":"GC Zondag","year":"1995","unstructured":"Zondag GC, Koningstein GM, Jiang YP, Sap J, Moolenaar WH, Gebbink MF. Homophilic interactions mediated by receptor tyrosine phosphatases mu and kappa. A critical role for the novel extracellular MAM domain. J Biol Chem. 1995;16(24):14247\u201350. https:\/\/doi.org\/10.1074\/jbc.270.24.14247.","journal-title":"J Biol Chem Jun"},{"issue":"15","key":"6496_CR28","doi-asserted-by":"publisher","first-page":"10173","DOI":"10.1074\/jbc.274.15.10173","volume":"9","author":"T Muller","year":"1999","unstructured":"Muller T, Choidas A, Reichmann E, Ullrich A. Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem. 1999;9(15):10173\u201383. https:\/\/doi.org\/10.1074\/jbc.274.15.10173.","journal-title":"J Biol Chem Apr"},{"issue":"8","key":"6496_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/s0300-9084(97)82739-3","volume":"79","author":"GC Zondag","year":"1997","unstructured":"Zondag GC, Moolenaar WH. Receptor protein tyrosine phosphatases: involvement in cell-cell interaction and signaling. Biochimie. 1997;79(8):477\u201383. https:\/\/doi.org\/10.1016\/s0300-9084(97)82739-3.","journal-title":"Biochimie Sep"},{"issue":"2","key":"6496_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0955-0674(00)00196-4","volume":"13","author":"NK Tonks","year":"2001","unstructured":"Tonks NK, Neel BG. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol. 2001;13(2):182\u201395. https:\/\/doi.org\/10.1016\/s0955-0674(00)00196-4.","journal-title":"Curr Opin Cell Biol Apr"},{"issue":"5","key":"6496_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cellsig.2007.12.024","volume":"20","author":"L Novellino","year":"2008","unstructured":"Novellino L, De Filippo A, Deho P, et al. PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin\/E-cadherin complexes in cancer cells. Cell Signal. 2008;20(5):872\u201383. https:\/\/doi.org\/10.1016\/j.cellsig.2007.12.024.","journal-title":"Cell Signal May"},{"issue":"7","key":"6496_CR32","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"25","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;25(7):1117\u201334. https:\/\/doi.org\/10.1016\/j.cell.2010.06.011.","journal-title":"Cell Jun"},{"issue":"5","key":"6496_CR33","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1073\/pnas.94.5.1680","volume":"4","author":"AJ Flint","year":"1997","unstructured":"Flint AJ, Tiganis T, Barford D, Tonks NK. Development of substrate-trapping mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci U S. 1997;4(5):1680\u20135. https:\/\/doi.org\/10.1073\/pnas.94.5.1680.","journal-title":"Proc Natl Acad Sci U S Mar"},{"issue":"3","key":"6496_CR34","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1128\/MCB.18.3.1622","volume":"18","author":"T Tiganis","year":"1998","unstructured":"Tiganis T, Bennett AM, Ravichandran KS, Tonks NK. Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol Cell Biol. 1998;18(3):1622\u201334. https:\/\/doi.org\/10.1128\/MCB.18.3.1622.","journal-title":"Mol Cell Biol Mar"},{"issue":"22","key":"6496_CR35","doi-asserted-by":"publisher","first-page":"19470","DOI":"10.1074\/jbc.M201097200","volume":"31","author":"Z Wang","year":"2002","unstructured":"Wang Z, Wang M, Lazo JS, Carr BI. Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem. 2002;31(22):19470\u20135. https:\/\/doi.org\/10.1074\/jbc.M201097200.","journal-title":"J Biol Chem May"},{"issue":"11","key":"6496_CR36","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1128\/MCB.25.11.4703-4715.2005","volume":"25","author":"SE Wang","year":"2005","unstructured":"Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor beta (TGF-beta)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-beta function. Mol Cell Biol. 2005;25(11):4703\u201315. https:\/\/doi.org\/10.1128\/MCB.25.11.4703-4715.2005.","journal-title":"Mol Cell Biol Jun"},{"issue":"52","key":"6496_CR37","doi-asserted-by":"publisher","first-page":"42694","DOI":"10.1074\/jbc.M507722200","volume":"30","author":"Y Xu","year":"2005","unstructured":"Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ. Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J Biol Chem. 2005;30(52):42694\u2013700. https:\/\/doi.org\/10.1074\/jbc.M507722200.","journal-title":"J Biol Chem Dec"},{"issue":"4","key":"6496_CR38","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/pmic.200500400","volume":"6","author":"YS Kim","year":"2006","unstructured":"Kim YS, Kang HY, Kim JY, et al. Identification of target proteins of N-acetylglucosaminyl transferase V in human colon cancer and implications of protein tyrosine phosphatase kappa in enhanced cancer cell migration. Proteom. 2006;6(4):1187\u201391. https:\/\/doi.org\/10.1002\/pmic.200500400.","journal-title":"Proteom Feb"},{"issue":"1","key":"6496_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.abb.2009.02.005","volume":"1","author":"C Wang","year":"2009","unstructured":"Wang C, Yang Y, Yang Z, et al. EGF-mediated migration signaling activated by N-acetylglucosaminyltransferase-V via receptor protein tyrosine phosphatase kappa. Arch Biochem Biophys. 2009;1(1):64\u201372. https:\/\/doi.org\/10.1016\/j.abb.2009.02.005.","journal-title":"Arch Biochem Biophys Jun"},{"issue":"9","key":"6496_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrm909","volume":"3","author":"DE Levy","year":"2002","unstructured":"Levy DE, Darnell JE. Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651\u201362. https:\/\/doi.org\/10.1038\/nrm909.","journal-title":"Nat Rev Mol Cell Biol Sep"},{"issue":"11","key":"6496_CR41","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798\u2013809. https:\/\/doi.org\/10.1038\/nrc2734.","journal-title":"Nat Rev Cancer Nov"},{"issue":"21","key":"6496_CR42","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1038\/sj.onc.1203476","volume":"15","author":"J Bromberg","year":"2000","unstructured":"Bromberg J, Darnell JE Jr. The role of stats in transcriptional control and their impact on cellular function. Oncogene. 2000;15(21):2468\u201373. https:\/\/doi.org\/10.1038\/sj.onc.1203476.","journal-title":"Oncogene May"},{"issue":"9","key":"6496_CR43","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1172\/JCI15617","volume":"109","author":"J Bromberg","year":"2002","unstructured":"Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109(9):1139\u201342. https:\/\/doi.org\/10.1172\/JCI15617.","journal-title":"J Clin Invest May"},{"issue":"2","key":"6496_CR44","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/leu.2013.192","volume":"28","author":"KA Dorritie","year":"2014","unstructured":"Dorritie KA, McCubrey JA, Johnson DE. STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leuk. 2014;28(2):248\u201357. https:\/\/doi.org\/10.1038\/leu.2013.192.","journal-title":"Leuk Feb"},{"issue":"4","key":"6496_CR45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/1078-0432.CCR-22-0997","volume":"16","author":"H Chen","year":"2023","unstructured":"Chen H, Zhou W, Bian A, et al. Selectively targeting STAT3 using a small molecule inhibitor is a potential therapeutic strategy for pancreatic Cancer. Clin Cancer Res. 2023;16(4):815\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0997.","journal-title":"Clin Cancer Res Feb"},{"issue":"11","key":"6496_CR46","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1128\/MCB.17.11.6508","volume":"17","author":"J Chung","year":"1997","unstructured":"Chung J, Uchida E, Grammer TC, Blenis J. STAT3 Serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 1997;17(11):6508\u201316. https:\/\/doi.org\/10.1128\/MCB.17.11.6508.","journal-title":"Mol Cell Biol Nov"},{"key":"6496_CR47","doi-asserted-by":"publisher","first-page":"39517","DOI":"10.1038\/srep39517","volume":"6","author":"YS Xu","year":"2016","unstructured":"Xu YS, Liang JJ, Wang Y, et al. STAT3 undergoes Acetylation-dependent mitochondrial translocation to regulate pyruvate metabolism. Sci Rep. 2016;6:39517. https:\/\/doi.org\/10.1038\/srep39517.","journal-title":"Sci Rep Dec 22"},{"issue":"50","key":"6496_CR48","doi-asserted-by":"publisher","first-page":"21499","DOI":"10.1073\/pnas.1016147107","volume":"14","author":"J Yang","year":"2010","unstructured":"Yang J, Huang J, Dasgupta M, et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S. 2010;14(50):21499\u2013504. https:\/\/doi.org\/10.1073\/pnas.1016147107.","journal-title":"Proc Natl Acad Sci U S Dec"},{"issue":"29","key":"6496_CR49","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.2174\/1381612823666170616082125","volume":"16","author":"M Kim","year":"2017","unstructured":"Kim M, Baek M, Kim DJ. Protein tyrosine signaling and its potential therapeutic implications in carcinogenesis. Curr Pharm Des. 2017;16(29):4226\u201346. https:\/\/doi.org\/10.2174\/1381612823666170616082125.","journal-title":"Curr Pharm Des Nov"},{"key":"6496_CR50","doi-asserted-by":"publisher","unstructured":"Kim M, Morales LD, Jang IS, Cho YY, Kim DJ. Protein tyrosine phosphatases as potential regulators of STAT3 signaling. Int J Mol Sci. 2018;11(9). https:\/\/doi.org\/10.3390\/ijms19092708.","DOI":"10.3390\/ijms19092708"},{"issue":"10","key":"6496_CR51","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","volume":"5","author":"YW Chen","year":"2015","unstructured":"Chen YW, Guo T, Shen L, et al. Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma. Blood. 2015;5(10):1589\u2013600. https:\/\/doi.org\/10.1182\/blood-2014-07-588970.","journal-title":"Blood Mar"},{"key":"6496_CR52","doi-asserted-by":"publisher","first-page":"4265040","DOI":"10.1155\/2019\/4265040","volume":"2019","author":"X Xu","year":"2019","unstructured":"Xu X, Li D, Liu J, et al. Downregulation of PTPRK promotes cell proliferation and metastasis of NSCLC by enhancing STAT3 activation. Anal Cell Pathol (Amst). 2019;2019:4265040. https:\/\/doi.org\/10.1155\/2019\/4265040.","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"2","key":"6496_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3322\/caac.20003","volume":"59","author":"WW Ma","year":"2009","unstructured":"Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59(2):111\u201337. https:\/\/doi.org\/10.3322\/caac.20003.","journal-title":"CA Cancer J Clin Mar-Apr"},{"key":"6496_CR54","doi-asserted-by":"publisher","unstructured":"Vainonen JP, Momeny M, Westermarck J. Druggable cancer phosphatases. Sci Transl Med. 2021;7(588). https:\/\/doi.org\/10.1126\/scitranslmed.abe2967.","DOI":"10.1126\/scitranslmed.abe2967"},{"issue":"21","key":"6496_CR55","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/0008-5472.CAN-17-1510","volume":"1","author":"R Frankson","year":"2017","unstructured":"Frankson R, Yu ZH, Bai Y, Li Q, Zhang RY, Zhang ZY. Therapeutic targeting of oncogenic tyrosine phosphatases. Cancer Res. 2017;1(21):5701\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1510.","journal-title":"Cancer Res Nov"},{"issue":"4","key":"6496_CR56","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3892\/ijo.2017.3884","volume":"50","author":"PH Sun","year":"2017","unstructured":"Sun PH, Chen G, Mason M, Jiang WG, Ye L. Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors. Int J Oncol. 2017;50(4):1127\u201335. https:\/\/doi.org\/10.3892\/ijo.2017.3884.","journal-title":"Int J Oncol Apr"},{"issue":"1","key":"6496_CR57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/annrheumdis-2014-205790","volume":"75","author":"SM Stanford","year":"2016","unstructured":"Stanford SM, Aleman Muench GR, Bartok B, et al. TGFbeta responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness. Ann Rheum Dis. 2016;75(1):295\u2013302. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205790.","journal-title":"Ann Rheum Dis Jan"},{"issue":"7229","key":"6496_CR58","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature07589","volume":"29","author":"L Zhu","year":"2009","unstructured":"Zhu L, Gibson P, Currle DS, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nat. 2009;29(7229):603\u20137. https:\/\/doi.org\/10.1038\/nature07589.","journal-title":"Nat Jan"},{"key":"6496_CR59","doi-asserted-by":"publisher","unstructured":"Boivin D, Labbe D, Fontaine N, et al. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry. 2009;48(18):3998\u20134007. https:\/\/doi.org\/10.1021\/bi900159d","DOI":"10.1021\/bi900159d"},{"issue":"15","key":"6496_CR60","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/onc.2014.141","volume":"9","author":"O Shimozato","year":"2015","unstructured":"Shimozato O, Waraya M, Nakashima K, et al. Receptor-type protein tyrosine phosphatase kappa directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene. 2015;9(15):1949\u201360. https:\/\/doi.org\/10.1038\/onc.2014.141.","journal-title":"Oncogene Apr"},{"issue":"5","key":"6496_CR61","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/2211-5463.12636","volume":"9","author":"M Matsushita","year":"2019","unstructured":"Matsushita M, Mori Y, Uchiumi K, et al. PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct Inhibition of pro-oncogenic CD133. FEBS Open Bio. 2019;9(5):935\u201346. https:\/\/doi.org\/10.1002\/2211-5463.12636.","journal-title":"FEBS Open Bio May"},{"issue":"7413","key":"6496_CR62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nature11308","volume":"30","author":"BK Koo","year":"2012","unstructured":"Koo BK, Spit M, Jordens I, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nat. 2012;30(7413):665\u20139. https:\/\/doi.org\/10.1038\/nature11308.","journal-title":"Nat Aug"},{"issue":"7397","key":"6496_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nature11019","volume":"29","author":"HX Hao","year":"2012","unstructured":"Hao HX, Xie Y, Zhang Y, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nat. 2012;29(7397):195\u2013200. https:\/\/doi.org\/10.1038\/nature11019.","journal-title":"Nat Apr"},{"key":"6496_CR64","doi-asserted-by":"publisher","unstructured":"Chang LS, Kim M, Glinka A, Reinhard C, Niehrs C. The tumor suppressor PTPRK promotes ZNRF3 internalization and is required for Wnt Inhibition in the Spemann organizer. Elife. 2020;14(9). https:\/\/doi.org\/10.7554\/eLife.51248.","DOI":"10.7554\/eLife.51248"},{"issue":"4","key":"6496_CR65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/cne.903510410","volume":"23","author":"M Sahin","year":"1995","unstructured":"Sahin M, Dowling JJ, Hockfield S. Seven protein tyrosine phosphatases are differentially expressed in the developing rat brain. J Comp Neurol. 1995;23(4):617\u201331. https:\/\/doi.org\/10.1002\/cne.903510410.","journal-title":"J Comp Neurol Jan"},{"issue":"1\u20132","key":"6496_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0925-4773(97)00179-2","volume":"70","author":"M Fuchs","year":"1998","unstructured":"Fuchs M, Wang H, Ciossek T, Chen Z, Ullrich A. Differential expression of MAM-subfamily protein tyrosine phosphatases during mouse development. Mech Dev. 1998;70(1\u20132):91\u2013109. https:\/\/doi.org\/10.1016\/s0925-4773(97)00179-2.","journal-title":"Mech Dev Jan"},{"issue":"6","key":"6496_CR67","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1006\/mcne.1999.0758","volume":"13","author":"NE Drosopoulos","year":"1999","unstructured":"Drosopoulos NE, Walsh FS, Doherty P. A soluble version of the receptor-like protein tyrosine phosphatase kappa stimulates neurite outgrowth via a Grb2\/MEK1-dependent signaling cascade. Mol Cell Neurosci. 1999;13(6):441\u20139. https:\/\/doi.org\/10.1006\/mcne.1999.0758.","journal-title":"Mol Cell Neurosci Jun"},{"key":"6496_CR68","doi-asserted-by":"publisher","unstructured":"Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u20131590. https:\/\/doi.org\/10.1016\/S0140-6736(20)32205-4","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"6496_CR69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jpsychires.2017.09.021","volume":"96","author":"Y Chen","year":"2018","unstructured":"Chen Y, Xu C, Harirforoosh S, Luo X, Wang KS. Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer\u2019s disease, cancer risk, and cholesterol. J Psychiatr Res. 2018;96:65\u201372. https:\/\/doi.org\/10.1016\/j.jpsychires.2017.09.021.","journal-title":"J Psychiatr Res Jan"},{"issue":"1","key":"6496_CR70","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1460-9568.2005.04189.x","volume":"22","author":"U Ueberham","year":"2005","unstructured":"Ueberham U, Ueberham E, Bruckner MK, et al. Inducible neuronal expression of Transgenic TGF-beta1 in vivo: dissection of short-term and long-term effects. Eur J Neurosci. 2005;22(1):50\u201364. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.04189.x.","journal-title":"Eur J Neurosci Jul"},{"issue":"1\u20132","key":"6496_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jad.2008.10.021","volume":"116","author":"ML Hamshere","year":"2009","unstructured":"Hamshere ML, Gordon-Smith K, Forty L, et al. Age-at-onset in bipolar-I disorder: mixture analysis of 1369 cases identifies three distinct clinical sub-groups. J Affect Disord. 2009;116(1\u20132):23\u20139. https:\/\/doi.org\/10.1016\/j.jad.2008.10.021.","journal-title":"J Affect Disord Jul"},{"key":"6496_CR72","doi-asserted-by":"publisher","unstructured":"Network, Pathway Analysis Subgroup of Psychiatric Genomics C. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18(2):199\u2013209. https:\/\/doi.org\/10.1038\/nn.3922.","DOI":"10.1038\/nn.3922"},{"issue":"12","key":"6496_CR73","doi-asserted-by":"publisher","first-page":"e0168404","DOI":"10.1371\/journal.pone.0168404","volume":"11","author":"KN Chitrala","year":"2016","unstructured":"Chitrala KN, Nagarkatti P, Nagarkatti M. Prediction of possible biomarkers and novel pathways conferring risk to Post-Traumatic stress disorder. PLoS ONE. 2016;11(12):e0168404. https:\/\/doi.org\/10.1371\/journal.pone.0168404.","journal-title":"PLoS ONE"},{"key":"6496_CR74","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1038\/ncomms5998","volume":"22","author":"K Moreau","year":"2014","unstructured":"Moreau K, Fleming A, Imarisio S, et al. PICALM modulates autophagy activity and Tau accumulation. Nat Commun. 2014;22:5:4998. https:\/\/doi.org\/10.1038\/ncomms5998.","journal-title":"Nat Commun Sep"},{"key":"6496_CR75","doi-asserted-by":"publisher","first-page":"108171","DOI":"10.1016\/j.pharmthera.2022.108171","volume":"237","author":"M Eshraghi","year":"2022","unstructured":"Eshraghi M, Ahmadi M, Afshar S, et al. Enhancing autophagy in Alzheimer\u2019s disease through drug repositioning. Pharmacol Ther. 2022;237:108171. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108171.","journal-title":"Pharmacol Ther Sep"},{"key":"6496_CR76","doi-asserted-by":"publisher","first-page":"1026904","DOI":"10.3389\/fneur.2022.1026904","volume":"13","author":"N Luo","year":"2022","unstructured":"Luo N, Guo Y, Peng L, Deng F. High-fiber-diet-related metabolites improve neurodegenerative symptoms in patients with obesity with diabetes mellitus by modulating the hippocampal-hypothalamic endocrine axis. Front Neurol. 2022;13:1026904. https:\/\/doi.org\/10.3389\/fneur.2022.1026904.","journal-title":"Front Neurol"},{"key":"6496_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1146\/annurev.immunol.23.021704.115647","volume":"25","author":"LI Pao","year":"2007","unstructured":"Pao LI, Badour K, Siminovitch KA, Neel BG. Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol. 2007;25:473\u2013523. https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115647.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"6496_CR78","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.4049\/jimmunol.155.7.3281","volume":"1","author":"JC Cambier","year":"1995","unstructured":"Cambier JC. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol. 1995;1(7):3281\u20135.","journal-title":"J Immunol Oct"},{"issue":"7","key":"6496_CR79","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.4049\/jimmunol.160.7.3305","volume":"1","author":"LI Pao","year":"1998","unstructured":"Pao LI, Famiglietti SJ, Cambier JC. Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction. J Immunol. 1998;1(7):3305\u201314.","journal-title":"J Immunol Apr"},{"issue":"1","key":"6496_CR80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nri1530","volume":"5","author":"T Mustelin","year":"2005","unstructured":"Mustelin T, Vang T, Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol. 2005;5(1):43\u201357. https:\/\/doi.org\/10.1038\/nri1530.","journal-title":"Nat Rev Immunol Jan"},{"issue":"1","key":"6496_CR81","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2220\/biomedres.31.83","volume":"31","author":"R Iwata","year":"2010","unstructured":"Iwata R, Sasaki N, Agui T. Contiguous gene deletion of Ptprk and Themis causes T-helper immunodeficiency (thid) in the LEC rat. Biomed Res. 2010;31(1):83\u20137. https:\/\/doi.org\/10.2220\/biomedres.31.83.","journal-title":"Biomed Res Feb"},{"issue":"7359","key":"6496_CR82","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"10","author":"C Genetics","year":"2011","unstructured":"International Multiple Sclerosis, Genetics C, Wellcome Trust Case Control C, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nat. 2011;10(7359):214\u20139. https:\/\/doi.org\/10.1038\/nature10251.","journal-title":"Nat Aug"},{"issue":"11","key":"6496_CR83","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ng.2770","volume":"45","author":"C Genetics","year":"2013","unstructured":"International Multiple Sclerosis, Genetics C, Beecham AH, Patsopoulos NA, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353\u201360. https:\/\/doi.org\/10.1038\/ng.2770.","journal-title":"Nat Genet Nov"},{"issue":"4","key":"6496_CR84","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ng.543","volume":"42","author":"PC Dubois","year":"2010","unstructured":"Dubois PC, Trynka G, Franke L, et al. Multiple common variants for Celiac disease influencing immune gene expression. Nat Genet. 2010;42(4):295\u2013302. https:\/\/doi.org\/10.1038\/ng.543.","journal-title":"Nat Genet Apr"},{"issue":"3","key":"6496_CR85","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ejhg.2013.136","volume":"22","author":"C Bondar","year":"2014","unstructured":"Bondar C, Plaza-Izurieta L, Fernandez-Jimenez N, et al. THEMIS and PTPRK in Celiac intestinal mucosa: coexpression in disease and after in vitro Gliadin challenge. Eur J Hum Genet. 2014;22(3):358\u201362. https:\/\/doi.org\/10.1038\/ejhg.2013.136.","journal-title":"Eur J Hum Genet Mar"},{"issue":"1","key":"6496_CR86","doi-asserted-by":"publisher","first-page":"14137","DOI":"10.1038\/s41598-022-18296-4","volume":"19","author":"N Sandholm","year":"2022","unstructured":"Sandholm N, Rubio Garcia A, Pekalski ML, Inshaw JRJ, Cutler AJ, Todd JA. Thymocyte regulatory variant alters transcription factor binding and protects from type 1 diabetes in infants. Sci Rep. 2022;19(1):14137. https:\/\/doi.org\/10.1038\/s41598-022-18296-4.","journal-title":"Sci Rep Aug"},{"key":"6496_CR87","doi-asserted-by":"publisher","unstructured":"Yu ED, Wang H, da Silva Antunes R, et al. A population of CD4(+)CD8(+) Double-Positive T cells associated with risk of plasma leakage in dengue viral infection. Viruses. 2022;5(1). https:\/\/doi.org\/10.3390\/v14010090.","DOI":"10.3390\/v14010090"},{"key":"6496_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1744-9081-4-44","volume":"26","author":"AL Aspler","year":"2008","unstructured":"Aspler AL, Bolshin C, Vernon SD, Broderick G. Evidence of inflammatory immune signaling in chronic fatigue syndrome: A pilot study of gene expression in peripheral blood. Behav Brain Funct. 2008;26:4:44. https:\/\/doi.org\/10.1186\/1744-9081-4-44.","journal-title":"Behav Brain Funct Sep"},{"issue":"7568","key":"6496_CR89","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bmj.38933.585764.AE","volume":"16","author":"I Hickie","year":"2006","unstructured":"Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;16(7568):575. https:\/\/doi.org\/10.1136\/bmj.38933.585764.AE.","journal-title":"BMJ Sep"},{"key":"6496_CR90","doi-asserted-by":"publisher","first-page":"103237","DOI":"10.1016\/j.critrevonc.2021.103237","volume":"159","author":"C Sanchez-Romero","year":"2021","unstructured":"Sanchez-Romero C, Bologna-Molina R, de Paes O, et al. Extranodal NK\/T cell lymphoma, nasal type: an updated overview. Crit Rev Oncol Hematol. 2021;159:103237. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103237.","journal-title":"Crit Rev Oncol Hematol Mar"},{"issue":"4","key":"6496_CR91","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1046\/j.1365-2141.1997.3223139.x","volume":"98","author":"KF Wong","year":"1997","unstructured":"Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma\/leukaemia. Br J Haematol. 1997;98(4):922\u20136. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.3223139.x.","journal-title":"Br J Haematol Sep"},{"key":"6496_CR92","doi-asserted-by":"publisher","unstructured":"de Mel S, Soon GS, Mok Y, et al. The genomics and molecular biology of natural Killer\/T-Cell lymphoma: opportunities for translation. Int J Mol Sci. 2018;30(7). https:\/\/doi.org\/10.3390\/ijms19071931.","DOI":"10.3390\/ijms19071931"},{"issue":"4","key":"6496_CR93","first-page":"737","volume":"15","author":"M Nakamura","year":"2003","unstructured":"Nakamura M, Kishi M, Sakaki T, et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 2003;15(4):737\u201341.","journal-title":"Cancer Res Feb"},{"issue":"5","key":"6496_CR94","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","volume":"99","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, Ifosfamide, L-asparaginase, and Etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5):1016\u201320. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00768.x.","journal-title":"Cancer Sci May"},{"key":"6496_CR95","doi-asserted-by":"publisher","unstructured":"Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432\u2013446. https:\/\/doi.org\/10.1016\/S0140-6736(18)30990-5","DOI":"10.1016\/S0140-6736(18)30990-5"},{"issue":"8","key":"6496_CR96","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/ccr3.1630","volume":"6","author":"V Camus","year":"2018","unstructured":"Camus V, Dubois S, Lepretre S, Jardin F, Tilly H. Prolonged third complete remission after Busulfan, Thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient. Clin Case Rep. 2018;6(8):1418\u201321. https:\/\/doi.org\/10.1002\/ccr3.1630.","journal-title":"Clin Case Rep Aug"},{"issue":"2","key":"6496_CR97","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00428-003-0836-9","volume":"443","author":"R Boonstra","year":"2003","unstructured":"Boonstra R, Koning A, Mastik M, van den Berg A, Poppema S. Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Arch. 2003;443(2):164\u20139. https:\/\/doi.org\/10.1007\/s00428-003-0836-9.","journal-title":"Virchows Arch Aug"},{"issue":"5","key":"6496_CR98","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0002-9440(10)65458-2","volume":"155","author":"CH Rickert","year":"1999","unstructured":"Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W. Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol. 1999;155(5):1445\u201351. https:\/\/doi.org\/10.1016\/S0002-9440(10)65458-2.","journal-title":"Am J Pathol Nov"},{"issue":"1","key":"6496_CR99","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1750-3639.2000.tb00244.x","volume":"10","author":"T Weber","year":"2000","unstructured":"Weber T, Weber RG, Kaulich K, et al. Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol. 2000;10(1):73\u201384. https:\/\/doi.org\/10.1111\/j.1750-3639.2000.tb00244.x.","journal-title":"Brain Pathol Jan"},{"issue":"29","key":"6496_CR100","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1200\/JCO.2008.16.1455","volume":"10","author":"FM Cady","year":"2008","unstructured":"Cady FM, O\u2019Neill BP, Law ME, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol. 2008;10(29):4814\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.16.1455.","journal-title":"J Clin Oncol Oct"},{"issue":"22","key":"6496_CR101","doi-asserted-by":"publisher","first-page":"22869","DOI":"10.18632\/aging.103982","volume":"16","author":"M Yi","year":"2020","unstructured":"Yi M, Zhou L, Li A, Luo S, Wu K. Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging (Albany NY). 2020;16(22):22869\u201391. https:\/\/doi.org\/10.18632\/aging.103982.","journal-title":"Aging (Albany NY) Nov"},{"issue":"1","key":"6496_CR102","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"17","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;17(1):82. https:\/\/doi.org\/10.1038\/s41408-023-00853-3.","journal-title":"Blood Cancer J May"},{"issue":"16","key":"6496_CR103","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"15","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;15(16):1541\u201352. https:\/\/doi.org\/10.1056\/NEJMra1400972.","journal-title":"N Engl J Med Oct"},{"key":"6496_CR104","doi-asserted-by":"publisher","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u20131162. https:\/\/doi.org\/10.1016\/S0140-6736(19)33018-1","DOI":"10.1016\/S0140-6736(19)33018-1"},{"issue":"4","key":"6496_CR105","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/leu.2013.270","volume":"28","author":"WS Stevenson","year":"2014","unstructured":"Stevenson WS, Best OG, Przybylla A, et al. DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leuk. 2014;28(4):787\u201393. https:\/\/doi.org\/10.1038\/leu.2013.270.","journal-title":"Leuk Apr"},{"key":"6496_CR106","doi-asserted-by":"publisher","unstructured":"Bienz M, Ramdani S, Knecht H. Molecular pathogenesis of hodgkin lymphoma: past, present, future. Int J Mol Sci. 2020;10(18). https:\/\/doi.org\/10.3390\/ijms21186623.","DOI":"10.3390\/ijms21186623"},{"issue":"2","key":"6496_CR107","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116\u201332. https:\/\/doi.org\/10.3322\/caac.21438.","journal-title":"CA Cancer J Clin Mar"},{"issue":"18","key":"6496_CR108","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","volume":"121","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013;121(18):3547\u201353. https:\/\/doi.org\/10.1182\/blood-2012-09-454694.","journal-title":"Blood May 2"},{"issue":"2","key":"6496_CR109","first-page":"257","volume":"49","author":"X Guo","year":"2020","unstructured":"Guo X, Liu G, Xie X, et al. Expressions of CD23, IL-17 and MMP-9 in patients with colorectal Cancer. Iran J Public Health. 2020;49(2):257\u201366.","journal-title":"Iran J Public Health Feb"},{"issue":"7407","key":"6496_CR110","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"18","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nat. 2012;18(7407):330\u20137. https:\/\/doi.org\/10.1038\/nature11252.","journal-title":"Nat Jul"},{"issue":"3","key":"6496_CR111","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/hep.32328","volume":"76","author":"S Annunziato","year":"2022","unstructured":"Annunziato S, Sun T, Tchorz JS. The RSPO-LGR4\/5-ZNRF3\/RNF43 module in liver homeostasis, regeneration, and disease. Hepatol. 2022;76(3):888\u201399. https:\/\/doi.org\/10.1002\/hep.32328.","journal-title":"Hepatol Sep"},{"issue":"47","key":"6496_CR112","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/s41388-021-02059-y","volume":"40","author":"EJ Ter Steege","year":"2021","unstructured":"Ter Steege EJ, Bakker ERM. The role of R-spondin proteins in cancer biology. Oncogene. 2021;40(47):6469\u201378. https:\/\/doi.org\/10.1038\/s41388-021-02059-y.","journal-title":"Oncogene Nov"},{"issue":"2","key":"6496_CR113","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/path.4709","volume":"239","author":"S Sekine","year":"2016","unstructured":"Sekine S, Yamashita S, Tanabe T, et al. Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma. J Pathol. 2016;239(2):133\u20138. https:\/\/doi.org\/10.1002\/path.4709.","journal-title":"J Pathol Jun"},{"key":"6496_CR114","doi-asserted-by":"publisher","first-page":"15945","DOI":"10.1038\/ncomms15945","volume":"11","author":"T Han","year":"2017","unstructured":"Han T, Schatoff EM, Murphy C, et al. R-Spondin chromosome rearrangements drive Wnt-dependent tumour initiation and maintenance in the intestine. Nat Commun. 2017;11:8:15945. https:\/\/doi.org\/10.1038\/ncomms15945.","journal-title":"Nat Commun Jul"},{"issue":"12","key":"6496_CR115","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1136\/gutjnl-2019-320019","volume":"69","author":"HHN Yan","year":"2020","unstructured":"Yan HHN, Siu HC, Ho SL, et al. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles. Gut. 2020;69(12):2165\u201379. https:\/\/doi.org\/10.1136\/gutjnl-2019-320019.","journal-title":"Gut Dec"},{"key":"6496_CR116","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.biopha.2017.06.047","volume":"93","author":"Y Xu","year":"2017","unstructured":"Xu Y, Ge K, Lu J, Huang J, Wei W, Huang Q. MicroRNA-493 suppresses hepatocellular carcinoma tumorigenesis through down-regulation of anthrax toxin receptor 1 (ANTXR1) and R-Spondin 2 (RSPO2). Biomed Pharmacother. 2017;93:334\u201343. https:\/\/doi.org\/10.1016\/j.biopha.2017.06.047.","journal-title":"Biomed Pharmacother"},{"issue":"7413","key":"6496_CR117","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature11282","volume":"30","author":"S Seshagiri","year":"2012","unstructured":"Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nat. 2012;30(7413):660\u20134. https:\/\/doi.org\/10.1038\/nature11282.","journal-title":"Nat Aug"},{"issue":"7584","key":"6496_CR118","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature16466","volume":"7","author":"EE Storm","year":"2016","unstructured":"Storm EE, Durinck S, de Sousa e Melo F, et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nat. 2016;7(7584):97\u2013100. https:\/\/doi.org\/10.1038\/nature16466.","journal-title":"Nat Jan"},{"key":"6496_CR119","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A, Cancer statistics. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"issue":"6","key":"6496_CR120","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin Nov"},{"issue":"5","key":"6496_CR121","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1164\/rccm.200504-531OE","volume":"1","author":"SG Spiro","year":"2005","unstructured":"Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;1(5):523\u20139. https:\/\/doi.org\/10.1164\/rccm.200504-531OE.","journal-title":"Am J Respir Crit Care Med Sep"},{"issue":"1","key":"6496_CR122","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1756-9966-29-22","volume":"10","author":"T Yoshizaki","year":"2010","unstructured":"Yoshizaki T, Motomura W, Tanno S, et al. Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth Inhibition in non-small-cell lung cancer cells. J Exp Clin Cancer Res. 2010;10(1):22. https:\/\/doi.org\/10.1186\/1756-9966-29-22.","journal-title":"J Exp Clin Cancer Res Mar"},{"issue":"5","key":"6496_CR123","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.prp.2018.02.002","volume":"214","author":"L Xu","year":"2018","unstructured":"Xu L, Xu X, Huang H, et al. MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK. Pathol Res Pract. 2018;214(5):776\u201383. https:\/\/doi.org\/10.1016\/j.prp.2018.02.002.","journal-title":"Pathol Res Pract May"},{"issue":"1","key":"6496_CR124","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin Jan"},{"issue":"6","key":"6496_CR125","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.juro.2017.05.074","volume":"198","author":"DJ Lee","year":"2017","unstructured":"Lee DJ, Mallin K, Graves AJ, et al. Recent changes in prostate Cancer screening practices and epidemiology. J Urol. 2017;198(6):1230\u201340. https:\/\/doi.org\/10.1016\/j.juro.2017.05.074.","journal-title":"J Urol Dec"},{"issue":"5","key":"6496_CR126","first-page":"333","volume":"15","author":"JD Garisto","year":"2017","unstructured":"Garisto JD, Klotz L. Active surveillance for prostate cancer: how to do it right. Oncol (Williston Park). 2017;15(5):333\u201340.","journal-title":"Oncol (Williston Park) May"},{"issue":"5","key":"6496_CR127","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3892\/ijo.2013.2082","volume":"43","author":"PH Sun","year":"2013","unstructured":"Sun PH, Ye L, Mason MD, Jiang WG. Receptor-like protein tyrosine phosphatase kappa negatively regulates the apoptosis of prostate cancer cells via the JNK pathway. Int J Oncol. 2013;43(5):1560\u20138. https:\/\/doi.org\/10.3892\/ijo.2013.2082.","journal-title":"Int J Oncol Nov"},{"issue":"30","key":"6496_CR128","doi-asserted-by":"publisher","first-page":"50240","DOI":"10.18632\/oncotarget.16933","volume":"25","author":"D Vanacore","year":"2017","unstructured":"Vanacore D, Boccellino M, Rossetti S, et al. Micrornas in prostate cancer: an overview. Oncotarget. 2017;25(30):50240\u201351. https:\/\/doi.org\/10.18632\/oncotarget.16933.","journal-title":"Oncotarget Jul"},{"issue":"1","key":"6496_CR129","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12894-017-0206-6","volume":"20","author":"HN Luu","year":"2017","unstructured":"Luu HN, Lin HY, Sorensen KD, et al. MiRNAs associated with prostate cancer risk and progression. BMC Urol. 2017;20(1):18. https:\/\/doi.org\/10.1186\/s12894-017-0206-6.","journal-title":"BMC Urol Mar"},{"issue":"19","key":"6496_CR130","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-17-3697","volume":"1","author":"F Simpkins","year":"2018","unstructured":"Simpkins F, Jang K, Yoon H, et al. Dual Src and MEK Inhibition decreases ovarian Cancer growth and targets tumor initiating Stem-Like cells. Clin Cancer Res. 2018;1(19):4874\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3697.","journal-title":"Clin Cancer Res Oct"},{"issue":"9","key":"6496_CR131","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1200\/JCO.2013.52.2284","volume":"20","author":"R Jagsi","year":"2014","unstructured":"Jagsi R, Jiang J, Momoh AO, et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the united States. J Clin Oncol. 2014;20(9):919\u201326. https:\/\/doi.org\/10.1200\/JCO.2013.52.2284.","journal-title":"J Clin Oncol Mar"},{"issue":"5","key":"6496_CR132","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.bjps.2005.10.033","volume":"60","author":"MH Mullan","year":"2007","unstructured":"Mullan MH, Wilkins EG, Goldfarb S, et al. Prospective analysis of psychosocial outcomes after breast reconstruction: cross-cultural comparisons of 1-year postoperative results. J Plast Reconstr Aesthet Surg. 2007;60(5):503\u20138. https:\/\/doi.org\/10.1016\/j.bjps.2005.10.033.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"21","key":"6496_CR133","doi-asserted-by":"publisher","first-page":"R1147","DOI":"10.1016\/j.cub.2017.09.019","volume":"6","author":"E Trefts","year":"2017","unstructured":"Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;6(21):R1147\u201351. https:\/\/doi.org\/10.1016\/j.cub.2017.09.019.","journal-title":"Curr Biol Nov"},{"issue":"2","key":"6496_CR134","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017.","journal-title":"J Hepatol Aug"},{"issue":"1","key":"6496_CR135","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.1038\/s41467-024-53733-0","volume":"4","author":"EH Gilglioni","year":"2024","unstructured":"Gilglioni EH, Li A, St-Pierre-Wijckmans W, et al. PTPRK regulates Glycolysis and de Novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity. Nat Commun. 2024;4(1):9522. https:\/\/doi.org\/10.1038\/s41467-024-53733-0.","journal-title":"Nat Commun Nov"},{"issue":"9698","key":"6496_CR136","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","volume":"17","author":"BT Hennessy","year":"2009","unstructured":"Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;17(9698):1371\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(09)61338-6.","journal-title":"Lancet Oct"},{"issue":"1","key":"6496_CR137","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13048-016-0278-z","volume":"18","author":"R Januchowski","year":"2016","unstructured":"Januchowski R, Sterzynska K, Zaorska K, et al. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;18(1):65. https:\/\/doi.org\/10.1186\/s13048-016-0278-z.","journal-title":"J Ovarian Res Oct"},{"issue":"10","key":"6496_CR138","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.7150\/jca.15371","volume":"7","author":"R Januchowski","year":"2016","unstructured":"Januchowski R, Swierczewska M, Sterzynska K, Wojtowicz K, Nowicki M, Zabel M. Increased expression of several collagen genes is associated with drug resistance in ovarian Cancer cell lines. J Cancer. 2016;7(10):1295\u2013310. https:\/\/doi.org\/10.7150\/jca.15371.","journal-title":"J Cancer"},{"key":"6496_CR139","doi-asserted-by":"publisher","unstructured":"Senthebane DA, Rowe A, Thomford NE, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017;21(7). https:\/\/doi.org\/10.3390\/ijms18071586.","DOI":"10.3390\/ijms18071586"},{"issue":"1\u20132","key":"6496_CR140","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drup.2012.01.006","volume":"15","author":"AL Correia","year":"2012","unstructured":"Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 2012;15(1\u20132):39\u201349. https:\/\/doi.org\/10.1016\/j.drup.2012.01.006.","journal-title":"Feb-Apr"},{"key":"6496_CR141","doi-asserted-by":"publisher","first-page":"241763","DOI":"10.1155\/2013\/241763","volume":"2013","author":"R Januchowski","year":"2013","unstructured":"Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013;2013:241763. https:\/\/doi.org\/10.1155\/2013\/241763.","journal-title":"Biomed Res Int"},{"key":"6496_CR142","doi-asserted-by":"publisher","unstructured":"Wojtowicz K, Sterzynska K, Swierczewska M, Nowicki M, Zabel M, Januchowski R. Piperine targets different drug resistance mechanisms in human ovarian Cancer cell lines leading to increased sensitivity to cytotoxic drugs. Int J Mol Sci. 2021;19(8). https:\/\/doi.org\/10.3390\/ijms22084243.","DOI":"10.3390\/ijms22084243"},{"issue":"5","key":"6496_CR143","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10434-999-0467-8","volume":"6","author":"KM McMasters","year":"1999","unstructured":"McMasters KM, Sondak VK, Lotze MT, Ross MI. Recent advances in melanoma staging and therapy. Ann Surg Oncol. 1999;6(5):467\u201375. https:\/\/doi.org\/10.1007\/s10434-999-0467-8.","journal-title":"Ann Surg Oncol Jul-Aug"},{"issue":"2","key":"6496_CR144","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4062\/biomolther.2018.203","volume":"1","author":"H Kim","year":"2019","unstructured":"Kim H, Yi N, Do BR, Lee AY. Adipose-Derived stem cell coculturing stimulates Integrin-Mediated extracellular matrix adhesion of melanocytes by upregulating growth factors. Biomol Ther (Seoul). 2019;1(2):185\u201392. https:\/\/doi.org\/10.4062\/biomolther.2018.203.","journal-title":"Biomol Ther (Seoul)"},{"issue":"2","key":"6496_CR145","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/1523-1747.ep12616793","volume":"99","author":"PE de Wit","year":"1992","unstructured":"de Wit PE, Moretti S, Koenders PG, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol. 1992;99(2):168\u201373. https:\/\/doi.org\/10.1111\/1523-1747.ep12616793.","journal-title":"J Invest Dermatol Aug"},{"issue":"5","key":"6496_CR146","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1046\/j.0022-202x.2001.01534.x","volume":"117","author":"L McArdle","year":"2001","unstructured":"McArdle L, Rafferty M, Maelandsmo GM, et al. Protein tyrosine phosphatase genes downregulated in melanoma. J Invest Dermatol. 2001;117(5):1255\u201360. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01534.x.","journal-title":"J Invest Dermatol Nov"},{"key":"6496_CR147","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4615-3080-0_8","volume":"65","author":"AP Albino","year":"1993","unstructured":"Albino AP, Fountain JW. Molecular genetics of human malignant melanoma. Cancer Treat. 1993;65:201\u201355. https:\/\/doi.org\/10.1007\/978-1-4615-3080-0_8.","journal-title":"Cancer Treat Res"},{"issue":"1","key":"6496_CR148","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1038\/s41467-018-05941-8","volume":"5","author":"B Casar","year":"2018","unstructured":"Casar B, Badrock AP, Jimenez I, et al. RAS at the golgi antagonizes malignant transformation through PTPRkappa-mediated Inhibition of ERK activation. Nat Commun. 2018;5(1):3595. https:\/\/doi.org\/10.1038\/s41467-018-05941-8.","journal-title":"Nat Commun Sep"},{"issue":"2","key":"6496_CR149","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97\u2013109. https:\/\/doi.org\/10.1007\/s00401-007-0243-4.","journal-title":"Acta Neuropathol Aug"},{"issue":"10","key":"6496_CR150","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1200\/JCO.2005.03.089","volume":"1","author":"F Lefranc","year":"2005","unstructured":"Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005;1(10):2411\u201322. https:\/\/doi.org\/10.1200\/JCO.2005.03.089.","journal-title":"J Clin Oncol Apr"},{"issue":"4","key":"6496_CR151","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1586\/ern.09.10","volume":"9","author":"J Drappatz","year":"2009","unstructured":"Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009;9(4):519\u201334. https:\/\/doi.org\/10.1586\/ern.09.10.","journal-title":"Expert Rev Neurother Apr"},{"key":"6496_CR152","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev.pharmtox.42.083001.144616","volume":"42","author":"ZY Zhang","year":"2002","unstructured":"Zhang ZY. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol. 2002;42:209\u201334. https:\/\/doi.org\/10.1146\/annurev.pharmtox.42.083001.144616.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"6496_CR153","doi-asserted-by":"publisher","first-page":"107966","DOI":"10.1016\/j.pharmthera.2021.107966","volume":"230","author":"Y Song","year":"2022","unstructured":"Song Y, Zhao M, Zhang H, Yu B. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacol Ther. 2022;230:107966. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107966.","journal-title":"Pharmacol Ther Feb"},{"issue":"16","key":"6496_CR154","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1158\/0008-5472.CAN-15-2323","volume":"15","author":"Y Bai","year":"2016","unstructured":"Bai Y, Yu ZH, Liu S, et al. Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. Cancer Res. 2016;15(16):4805\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2323.","journal-title":"Cancer Res Aug"},{"key":"6496_CR155","doi-asserted-by":"publisher","first-page":"1340726","DOI":"10.3389\/fimmu.2024.1340726","volume":"15","author":"X Chen","year":"2024","unstructured":"Chen X, Keller SJ, Hafner P, et al. Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull\u2019s eye for targeted therapy? Front Immunol. 2024;15:1340726. https:\/\/doi.org\/10.3389\/fimmu.2024.1340726.","journal-title":"Front Immunol"},{"key":"6496_CR156","doi-asserted-by":"publisher","unstructured":"Wang P, Han Y, Pan W et al. Tyrosine phosphatase SHP2 aggravates tumor progression and Glycolysis by dephosphorylating PKM2 in gastric cancer. MedComm (2020). 2024;5(4):e527. https:\/\/doi.org\/10.1002\/mco2.527","DOI":"10.1002\/mco2.527"},{"key":"6496_CR157","doi-asserted-by":"publisher","unstructured":"Liu J, Wang Y, Lin L. Small molecules for fat combustion: targeting obesity. Acta Pharm Sin B. 2019;9(2):220\u201336. https:\/\/doi.org\/10.1016\/j.apsb.2018.09.007.","DOI":"10.1016\/j.apsb.2018.09.007"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06496-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06496-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06496-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:45:48Z","timestamp":1747028748000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06496-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6496"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06496-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Supplementary\n                      \n                      for details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Abbreviations"}},{"value":"The authors state that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"534"}}